Literature DB >> 2381135

[Acute myocardial uptake of lidocaine, mexiletine and amiodarone].

J Nitsch1, J Leffler, B Lüderitz.   

Abstract

To assess acute myocardial uptake of antiarrhythmic drugs, we measured drug concentrations simultaneously in the aorta and in the coronary sinus during diagnostic cardiac catheterization. Measurements were taken 1, 2, 3, 4, 5, 7, and 10 minutes after intravenous bolus application of lidocaine (n = 10, 25 mg), mexiletine (n = 5, 25 mg and n = 10, 100 mg), or amiodarone (n = 10, 25 mg). Drug levels were measured by high-pressure liquid chromatography. Maximal concentrations were observed after 2-5 min. After 3-5 min coronary sinus levels exceeded aorta levels, indicating the end of net myocardial drug uptake. In contrast to lidocaine and amiodarone, no mexiletine was found in the coronary sinus 15 s after the end of drug application, obviously indicating a high myocardial drug content. Furthermore, the data provide an explanation for the acute efficacy of amiodarone. The myocardial uptake may result in various pharmacodynamic effects of antiarrhythmic drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2381135     DOI: 10.1007/bf01667015

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  12 in total

1.  Effect of pH on the myocardial uptake and pharmacodynamics of propafenone in the isolated rabbit heart.

Authors:  A M Gillis; R E Kates
Journal:  J Cardiovasc Pharmacol       Date:  1988       Impact factor: 3.105

2.  Short-term myocardial uptake of lidocaine and mexiletine in patients with ischemic heart disease.

Authors:  J D Horowitz; M K Dynon; E Woodward; S T Sia; P S Macdonald; D J Morgan; A J Goble; W J Louis
Journal:  Circulation       Date:  1986-05       Impact factor: 29.690

3.  Distribution of propafenone and its active metabolite, 5-hydroxypropafenone, in human tissues.

Authors:  R Latini; S Marchi; E Riva; A Cavalli; M G Cazzaniga; A P Maggioni; A Volpi
Journal:  Am Heart J       Date:  1987-03       Impact factor: 4.749

4.  Lidocaine and its metabolites in canine plasma and myocardium.

Authors:  F Handel; F A Luzzi; T L Wenger; A Barchowsky; D G Shand; H C Strauss
Journal:  J Cardiovasc Pharmacol       Date:  1983 Jan-Feb       Impact factor: 3.105

5.  Intravenous mexiletine in management of lidocaine-resistant ventricular tachycardia.

Authors:  V Santinelli; M Chiariello; M Stanislao; M Condorelli
Journal:  Am Heart J       Date:  1983-04       Impact factor: 4.749

6.  Kinetics of antifibrillatory effects of bretylium: correlation with myocardial drug concentrations.

Authors:  J L Anderson; E Patterson; M Conlon; S Pasyk; B Pitt; B R Lucchesi
Journal:  Am J Cardiol       Date:  1980-10       Impact factor: 2.778

7.  Comparative trial of mexiletine and lignocaine in the treatment of early ventricular tachyarrhythmias after acute myocardial infarction.

Authors:  J D Horowitz; S N Anavekar; P M Morris; A J Goble; A E Doyle; W J Louis
Journal:  J Cardiovasc Pharmacol       Date:  1981 May-Jun       Impact factor: 3.105

8.  A model to describe myocardial drug disposition in the dog.

Authors:  R E Kates; P Jaillon
Journal:  J Pharmacol Exp Ther       Date:  1980-07       Impact factor: 4.030

9.  Amiodarone and desethylamiodarone distribution in the atrium and adipose tissue of patients undergoing short- and long-term treatment with amiodarone.

Authors:  E Barbieri; F Conti; P Zampieri; G P Trevi; P Zardini; V d'Aranno; R Latini
Journal:  J Am Coll Cardiol       Date:  1986-07       Impact factor: 24.094

10.  Intravenous amiodarone in the acute treatment of recurrent symptomatic ventricular tachycardia.

Authors:  F Morady; M M Scheinman; E Shen; W Shapiro; R J Sung; L DiCarlo
Journal:  Am J Cardiol       Date:  1983-01-01       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.